Oncology
09/2020

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

European Society for Medical Oncology (ESMO) Congress
Read More
Oncology
06/2019

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO
Read More
Oncology
12/2018

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium
Read More
Oncology
11/2018

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Read More
Oncology
10/2017

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD
Read More
Oncology
04/2017

First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting
Read More
Oncology
02/2017

Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Pharmacology and Therapeutics
Read More
Oncology
12/2016

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium
Read More
Oncology
12/2016

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine
Read More
Oncology
11/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference
Read More